ArticleImmunity2015
IL-2: Change Structure … Change Function.
Article in Immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Characterization of bovine interleukin-2 stably expressed in HEK-293 cells.The Journal of veterinary medical science · 2021Article
- Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy.Acta pharmacologica Sinica · 2020Review
- Injectable Polymeric Cytokine-Binding Nanowires Are Effective Tissue-Specific Immunomodulators.ACS nano · 2017Article
- Academic, Foundation, and Industry Collaboration in Finding New Therapies.The New England journal of medicine · 2017Review
- Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease.Nature reviews. Immunology · 2016Review
- Is Formulary of Maranta Arundinacea Clarias Gariepinus (F-MaCg) a Potential Immunostimulant?Avicenna journal of medical biotechnologyArticle
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
In this issue of Immunity, Spangler et al. and Mitra et al. demonstrate how structural changes in the IL-2 molecule alter interactions with the IL-2 receptor, leading to differential cellular targeting and biochemical responses and selective immune consequences.
Indexed as
Identifiers
25992850What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.